917110-29-3Relevant academic research and scientific papers
Synthesis of 3′-deoxy-3′-[18F]fluoro-1-β-D- xylofurano-syluracil ([18F]-FMXU) for PET
Alauddin, Mian M.,Balatoni,Gelovani
, p. 941 - 950 (2005)
The synthesis of a pyrimidine analog, 3′-deoxy-3′-[ 18F]-fluoro-1-β-D-xylofuranosyluracil ([18F]-FMXU) is reported. 5-Methyluridine 1 was converted to its dimethoxytrityl derivatives 2 and 3 as a mixture. After separation the 2′, 5′-
Antiviral activity of various 1-(2′-Deoxy-β- d -lyxofuranosyl), 1-(2′-Fluoro-β- d -xylofuranosyl), 1-(3′-Fluoro-β- d -arabinofuranosyl), and 2′-fluoro-2′,3′-didehydro-2′, 3′-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication
Srivastav, Naveen C.,Shakya, Neeraj,Mak, Michelle,Agrawal, Babita,Tyrrell, D. Lorne,Kumar, Rakesh
experimental part, p. 7156 - 7166 (2010/12/19)
Despite the existence of successful vaccine and antiviral therapies, infection with hepatitis B virus (HBV) continues to be a major global cause of acute and chronic liver disease and high mortality. We synthesized and evaluated several lyxofuranosyl, 2′-fluoroxylofuranosyl, 3′- fluoroarabinofuranosyl, and 2′-fluoro-2′,3′-didehydro- 2′,3′-dideoxyribose pyrimidine nucleoside analogues for antiviral activities against hepatitis B virus. Among the compounds examined, 1-(2-deoxy-β-d-lyxofuranosyl)thymine (23), 1-(2-deoxy-β-d- lyxofuranosyl)-5-trifluoromethyluracil (25), 1-(2-deoxy-2-fluoro-β-d- xylofuranosyl)uracil (38), 1-(2-deoxy-2-fluoro-β-d-xylofuranosyl)thymine (39), 2′,3′-dideoxy-2′,3′-didehydro-2′- fluorothymidine (48), and 2′,3′-dideoxy-2′,3′-didehydro- 2′-fluoro-5-ethyluridine (49) were found to possess significant anti-HBV activity against DHBV in primary duck hepatocytes with EC50 values of 4.1, 3.3, 40.6, 3.8, 0.2, and 39.0 μM, respectively. Compounds 23, 25, 39, 48, and 49 (EC50 = 41.3, 33.7, 19.2, 2.0-4.1, and 39.0 μM, respectively) exhibited significant activity against wild-type human HBV in 2.2.15 cells. Intriguingly, 25, 39, 48, and 49 retained sensitivity against lamivudine-resistant HBV containing a single mutation (M204I) and 48 emerged as an effective inhibitor of drug-resistant HBV with an EC50 of 4.1 μM. In contrast, 50% inhibition could not be achieved by lamivudine at 44 μM concentration in the drug-resistant strain. The compounds investigated did not show cytotoxicity to host cells up to the highest concentrations tested.
Anti-HCV nucleoside derivatives
-
, (2008/06/13)
The present invention comprises novel and known purine and pyrimidine nucleoside derivatives which have been discovered to be active against hepatitis C virus (HCV). The use of these derivatives for the treatment of HCV infection is claimed as are the novel nucleoside derivatives disclosed herein.
REMEDIES FOR HEPATITIS C
-
, (2008/06/13)
Excellent remedies for hepatitis C which contain as the active ingredients a 3'-deoxy-3'-fluorouridine derivatives and a 1-(3'-deoxy-fluoro-β-L-ribofuranosyl)uracil derivative and show little side effects.
1,2-Di-O-acetyl-5-O-benzoyl-3-deoxy-3-fluoro-D-xylofuranose. A versatile precursor for the synthesis of 3-deoxy-3-fluoro-β-D-xylofuranosyl nucleosides as potential antiviral agents
Gosselin,Puech,Genu-Dellac,Imbach
, p. 1 - 17 (2007/10/02)
The title compound has been synthesized from D-xylose for use in the preparation of 3-deoxy-3-fluoro-β-D-xylofuranosyl nucleoside analogues and their 2-deoxy derivatives, as exemplified in the guanine and thymine series. The title compound has been synthe
